Barclays
SLN

Barclays’s Silence Therapeutics SLN Stock Holding History

Barclays’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5K Sell
2,937
-2,128
-42% -$11.7K ﹤0.01% 4627
2025
Q4 		$30.8K Sell
5,065
-2,071
-29% -$13.3K ﹤0.01% 4817
2025
Q3 		$37K Buy
7,136
+101
+1% +$561 ﹤0.01% 4838
2025
Q2 		$40.8K Buy
7,035
+181
+3% +$776 ﹤0.01% 4734
2025
Q1 		$19.3K Buy
6,854
+728
+12% +$3.56K ﹤0.01% 4797
2024
Q4 		$42.1K Buy
6,126
+2,793
+84% +$36K ﹤0.01% 4791
2024
Q3 		$60.6K Sell
3,333
-2,237
-40% -$41.6K ﹤0.01% 4703
2024
Q2 		$106K Hold
5,570
– – ﹤0.01% 3879
2024
Q1 		$120K Buy
+5,570
New +$121K ﹤0.01% 4366

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Barclays's SLN Position: Q1 2026 in Review

Barclays reduced its Silence Therapeutics (SLN) stake by 42% in Q1 2026, selling an estimated $11.7K and leaving 2,937 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4627.

Barclays first reported a position in SLN in Q1 2024 and has held it in 9 quarters since. The position peaked at $120K in Q1 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Barclays held 2,937 shares of Silence Therapeutics worth $15.5K as of Q1 2026.
  • Barclays sold 2,128 Silence Therapeutics shares in Q1 2026, an estimated $11.7K.
  • Silence Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4627 holding.
  • Barclays first reported a position in Silence Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Barclays's Silence Therapeutics position peaked at $120K in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.